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Background: Only few reports exist on malignant thoracic neoplasms that require cardiopulmonary bypass during
resection. We aimed to investigate the early and late clinical outcome of these patients.
Methods: Patients with thoracic malignancies that underwent surgery between 2002 and 2014 were analyzed. All
patients had cardiopulomonary bypass support during resection. Clinical and perioperative data was retrospectively
reviewed for outcome and overall survival.
Results: Fifteen patients (12 female, mean age of 55 ± 15 years, range 24 to 80 years) were identified. Eleven (8
female) were diagnosed with primary thoracic malignomas and four with metastases. Three patients died early
postoperatively. Patients diagnosed with sarcoma had a significantly worse outcome than non-sarcoma patients
(83.3 ± 15.2 % after 1 year, 31.3 ± 24.5 % after 5 years vs. 83.3 ± 15.2 % after 1 year, 0 ± 0 % after 5 years, p = 0.005).
Conclusions: Malignancies with extension into cardiac structures or infiltration of great vessels can be resected
with cardiopulmonary bypass support and tolerable risk. Carefully selected patients can undergo advanced
operative procedures with an acceptable 1-year-survival, but only few patients achieved good long-term outcome.
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Thoracic malignancies invading the mediastinum, heart
or great vessels are rare and treatment including radical
resection challenges oncological therapists. Primary medi-
astinal neoplasms without invasion into adjacent structures
are generally of non-cardiac origin, such as thymoma,
lymphoma or neurogenic tumors. Tumors that infiltrate
directly into the heart, lung, aorta or vena cava are either
primary cardiac malignancies or metastases of distant
malignoma. The most common primary cardiac tumors
are sarcoma (especially rhabdomyosarcoma or angiosar-
coma) and lymphoma [1–6]. Once cardiac structures or
great vessels are widely infiltrated, patients are merely
treated in only a palliative setting due to an unresectable
situation. Nevertheless, very few of these patients might* Correspondence: rawa.arif@med.uni-heidelberg.de
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creativecommons.org/publicdomain/zero/1.0/qualify for surgery if local resection seems feasible. In these
patients cardiopulmonary bypass (CPB) and cardioplegic
cardiac arrest may be necessary in order to enable resec-
tion of infiltrated cardiac structures and subsequent recon-
struction [7–15]. This interdisciplinary approach requires
treatment at a cardiothoracic center and makes meticulous
planning within a tumor board mandatory. Nevertheless,
CPB-support for resection of advanced cardiothoracic ma-
lignancies increases the risk of bleeding from large wound
surfaces and may promote a dissemination of tumor cells.
Furthermore, immunological responses to extracorporeal
circulation bear further risks like lung injury or organ
dysfunction [16–19].
The clinical experience with these patients is very
limited. Therefore, we report our ten-year single-center
experience with patients suffering from thoracic malig-
noma who require the use of cardiopulmonary bypass
during resection.e distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Clinical data of patients that underwent surgery at our
institution between 01/2002 and 05/2014 was retrospect-
ively analyzed. Fifteen patients (12 female) with a mean
age of 55 ± 15 years (range 24 to 80 years) were finally
included. All patients had advanced thoracic malignan-
cies and cardiopulmonary bypass support during resec-
tion. Two of them underwent combined cardiac surgery
for coronary artery bypass grafting (CABG) in addition
to tumor resection. All patients were treated in a context
of interdisciplinary discussion including both local de-
partments of cardiac and thoracic surgery. Preoperative
routine staging included contrast enhanced ECG-gated
computed tomography (CT) (Fig. 1) and magnet reson-
ance imaging (MRI) of the chest. Clinical absence of
extrathoracic metastasis or active malignant disease was
a precondition for surgery. Five patients had diagnostic
biopsy prior to operation. Intraoperative transesophageal
echocardiography was performed in all patients. The site
of cannulation for CPB was selected depending on the
tumor localization. Conventional central bi-caval and
aortic cannulation was performed in 9 patients, two-
stage cannulation of the right atrium (RA) in 1 patient,
peripheral cannulation of groin vessels in 5 patients with
additional cannulation of internal jugular vein in 1 pa-
tient (patient #7). The diagnosis of a malignant tumorFig. 1 Preoperative computed tomography scan of patient 11. Carcinoid inwas made in 8 patients preoperatively. Final diagnosis
was achieved by intraoperative instantaneous section
and postoperative histology. Completeness of tumor re-
section was made by R classification as set by the
American Joint Committee on Cancer [20]. All patients
were finally debated in an interdisciplinary tumor board
concerning postoperative therapies. Adjuvant chemo-
therapy was advised on an individual basis and was
performed in 4 patients. Patient #6 denied adjuvant
chemotherapy.
Pre-, intra- and postoperative data was retrospectively
analyzed. End points were complications, overall survival
and individual outcome. Early events are defined as in-
hospital complications. Late events occurred after hos-
pital discharge. After approval of the institutional review
board, follow-up was obtained through contact with
general physicians or with the patient or family directly.
In accordance with the local ethic committee, the re-
quirement of individual patient consent was waived be-
cause of the study’s retrospective design and the data
collection from routine care. Mean follow-up time was
22 ± 30 months (range 4 to 112). Survival was estimated
by use of Kaplan-Meier method. Survival curves were
compared using log-rank test. Continuous variables are
shown as mean ± standard deviation or as range; cat-
egorical data as percentage.filtrating right lung and Vena cava superior
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Preoperative data
Eleven (8 female) patients were diagnosed with primary
thoracic malignancies and 4 patients (3 female) with meta-
static disease infiltrating cardiac structures and/or great
vessels (Table 1). Patients with mediastinal metastases were
free of local extrathoracic disease before cardiothoracic
surgery. Primary tumors of metastatic disease were chon-
drosarcoma (left heel; infiltration of middle lobe, right
lower lobe and left atrium (LA)), malign melanoma (infil-
tration of left lung (LL) and LA), osteosarcoma (left femur;
infiltration of left lower lobe (LLL) and LA) and rectum
carcinoma (infiltration of LL and LA).
Patients #1 and #9 were preoperatively diagnosed with
coronary artery disease (CAD) and required simultaneous
CABG. Patient characteristics, histological tumor diagnosis,Table 1 Patient characteristics, histological tumor diagnosis, localiza
aim and follow-up
Pts. No. Sex Age Histological diagnosis and
localization
Access Re













4 F 66 Intimal sarcoma, MPA and
RVOT with tumor thrombus
in RUL and RPA
Median sternotomy MP
thr
5 F 58 Chondrosarcoma
metastasis, ML, partial RLL
and LA
Right thoracotomy ML
6 F 49 Pleomorphic intimal
sarcoma, MPA, LPA and LL
Median sternotomy LL,
7 M 62 Thymic carcinoma, VCS and
portions within RA
Median sternotomy Tu
8 F 57 Melanoma metastasis, LL
and partial LA
Clamshell LL,
9 F 65 Pleomorphic
rhabdomyosarcoma, LA
Median sternotomy Tu
10 F 24 Osteosarcoma metastasis,
LLL and partial LA
Left thoracotomy LLL
11 M 45 Carcinoid, RL, Aorta, RA and
VCS
Clamshell RL




13 M 40 Undifferentiated sarcoma




14 F 46 NSCLC (adenocarcinoma)
RL infiltrating LV and MV
Hemi-clamshell RL
me
15 F 61 Rectum carcinoma
metastasis, LL, LA
Clamshell LL,
Pts. patients, LA left atrium, RA right atrium, MPA main pulmonary artery, RPA right
tract, ML middle lobe, RUL right upper lobe, RLL right lower lobe, LLL left lower lobe
system, C curative, P palliative, PM papillary muscle, NSCLC non small cell lung carcioperative access, resected structures, R- status, intent of re-
section approach and follow-up are shown in Table 1.
Operative data
Operation time was 303 ± 182 min (range 140 to 800 min)
and CPB time 151 ± 99 min (range 75 to 405 min). Six pa-
tients required aortic cross-clamping (53 ± 65 min; range
36 to 173 min). Intraoperative hypothermic levels were set
at 31.8 ± 3.8° Celsius (range 20 to 34° Celsius). No patient
required total circulatory arrest. Four patients received
auto-transfusion with cell-saver blood. Blood cell transfu-
sion requirements measured 3433 ± 5743 ml (range 0 to
19,000 ml). Surgical access to the mediastinum and thoracic
cavity was guaranteed through median sternotomy (n = 8),
clamshell-incision (n = 4) and lateral thoracotomy (n = 3).











None, C 0.07 Dead R0
mor anterior
diastinum
None, C 112.3 Alive R1
situ LA, posterior
diastinum, Tumor
None, P 0.67 Dead R?
A, RVOT, tumor
ombus
None, C 19 Dead R0, lung
metastasis
, partial RLL, LA Chemo, P 54.8 Alive R0
MPA, LPA None, C 21.3 Dead R1, progressive
recurrence in PA
mor, VCS None, C 33.4 Dead R1, unclear
partial LA None, C 45.4 Alive R0, CNS metastasis
mor, partial LA None, C 7.2 Dead R1, local
recurrence
, partial LA Chemo, C 25.8 Dead Questionable R1,
CNS metastasis
, VCS Chemo, P 0.00 Dead R?
mor, Aortic
ventitia
None, C 4.7 Alive R0
, MPA + LPA Chemo, C 4.3 Alive R0
, MV + posterior-
d. PM
Chemo, C 3.53 Dead R1, lung metastasis
partial LA Chemo, C 3.2 Alive R0
pulmonary artery, LPA left pulmonary artery, RVOT right ventricular outflow
, LL left lung, RL right lung, VCS vena cava superior, CNS central nervous
noma, MV mitral valve, PM papillary muscle
Arif et al. Journal of Cardiothoracic Surgery  (2015) 10:87 Page 4 of 8Circulatory support by IABP was performed in patient #1,
who simultaneously underwent CABG, and in patients #3
and #4 due to cardiac low output.
Patient #3 suffered from malignant paraganglioma lo-
cated in the posterior mediastinum with extended infil-
tration into the left atrium. Complete resection required
ex situ tumor removal of the heart with subsequent
cardiac auto-transplantation (Figs. 2 and 3): After insti-
tution of CPB following bi-caval and ascending aortic
cannulation, the heart was explanted. The tumor mass
infiltrating the entire left atrial wall was resected respect-
ing a 5 mm margin alongside the atrioventricular junc-
tion (Figs. 3 and 4). After resection of the extracardial
tumor portion up to the vertebral column, a left neo-
atrium was created using glutaraldehyd preserved au-
tologous pericardium anastomosed to both pulmonary
vein cuffs. Then, the explanted heart was re-implanted
suturing the left atrial wall margin to the neoatrium.
After auto-transplantation and weaning from CPB with
support of an IABP the thorax was left open and covered
with a Goretex membrane. The patient was transferred
to ICU. After subsequent ECMO implantation the pa-
tient died due to multi organ failure on 19th POD.
Complete resection (R0) was pathologically confirmed in 6
cases, 4 patients had tumor-positive resection margins
microscopically (R1). R-status remained unclear in 3 patients.Fig. 2 Preoperative magnetic resonance scan of patient 3. ParagangliomaPostoperative course and outcome
One patient (#11) died intraoperatively due to right hart
failure. Two patients died early postoperatively (within
30 days) due to multiorgan failure at POD 1 and 19. All
other patients (n = 12) survived the early postoperative
course. Overall ventilation time was 2.5 ± 4.9 days (range
0 to 20 d), in hospital survivors 1.3 ± 0.9 days (range 1 to
4 d) respectively, Overall ICU stay was 4.6 ± 5.4 days
(range 1 to 20 d), in hospital survivors 3.3 ± 2.5 days
(range 1 to 4 d) respectively.
Postoperative early and late morbidity is shown in
Table 2. Complications requiring surgical intervention
were recurrent pleural effusion (2 patients) and develop-
ment of hemothorax (1 patient). Two patients received
adjuvant chemotherapy, one patient postoperative medi-
astinal irradiation. Four patients underwent combined
radio- and chemotherapy.
Local recurrence of disease emerged in 2 patients. One
of these (patient #6) underwent re-surgery within 1 year
after primary therapy with R1 resection status. Salvage
surgery was performed in a palliative intent to reduce a
left atrial tumor mass. Nevertheless, that patient died
due to left atrial tumor occlusion and consecutive
cardiac output failure during the further postoperative
course. 3 patients developed lung and brain metastases
and received individual oncological therapy.of the posterior mediastinum infiltrating left atrium completely
Fig. 3 Intraoperative photograph of patient 3. Left atrium is completely
infiltrated by paraganglioma
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28 ± 13 % at 5 years (Fig. 5a). Mean Follow- up was 22 ±
30 months (range 4 to 112), six patients are alive at the
end of follow-up. Survival in patients with sarcoma hist-
ology (80 ± 18 % after 1 year, 20 ± 18 % after 5 years) was
found significantly poorer than survival in patients with
other dignities (53 ± 17 % after 1 year, 36 ± 19 % after
5 years, p = 0.006).
Discussion
There are only few reports of patients undergoing resec-
tion of thoracic malignancies with locally advanced inva-
sion into the heart and great central vessels. Molina at
al. described an incidence of primary cardiac tumors of
0.002 % in an autopsy series [3]. 75 % of primary cardiac
tumors are benign with 2/3 of them being diagnosed as
myxoma. One quarter of patients suffers from tumorsFig. 4 Intraoperative photograph of patient 3. Left atrium is resected
ex vivo after temporary heart explantation and prepared
for re-implantationwith sarcoma histology, merely angiosarcoma or intimal
sarcoma of great vessels. Unfortunately, most patients
were initially found with locally advanced disease and
infiltration of adjacent vital structures. Therefore, ther-
apies remained mainly palliative employing conservative
chemo- or radiotherapy. Since the early 1990s, first re-
ports favored surgical treatment of malignancies infil-
trating cardiac structures by showing improved survival
compared to conservative treatment in selected patients
[4, 5]. With further improvement of perioperative man-
agement including ventilation strategies, circulatory assist-
ance and adjuvant procedures, curative therapy appeared
achievable. However, if cardiac structures or great vessels
are infiltrated, R0 resection remains challenging and extra-
corporeal circulation is often required.
Nevertheless, CPB implies several risks. The need of
full heparinization may cause excessive bleeding from
the surgical field, especially if additional extended lung
resection is required. We observed prolonged postsurgi-
cal bleeding in 3 of our patients, but only one (patient
#6) required redo surgery by videothoracoscopy after
development of a hemothorax. Therefore bleeding com-
plications were relatively low in our cohort. Another re-
ported risk of CPB is the possibility of intraoperative
tumor spilling, probably supported by venous drainage
into the reservoir and re-circulation within the open sys-
tem of CPB. Four of our patients developed distant me-
tastases, 2 of them after initially complete (R0) resection.
One of these suffered from malign melanoma, which is
principally associated with a high risk of systemic tumor
spread. Unless we did not observe an association with
CPB-use and early development of distant metastasis,
the avoidance of re-draining suctioned blood from the
surgical field into the corporal system might reduce the
risk of cell spilling in malignant surgery.
Third, immune modulatory effects are well described
and remain a risk for patients undergoing surgery with
use of extracorporeal circulation. In addition, patients
with lung disease bear a greater risk for pulmonary
failure and long-term ventilation after surgery involving
CPB [18, 19].
Our cohort includes 8 patients that underwent partial
lung resection (n = 2) or even pneumonectomy (n = 6).
Only one of them (patient #11) died intra-operatively
due to right heart failure. The other 7 patients showed a
median survival of 20 months (range 3 to 55 months)
without developing lung or circulatory failure within the
early postoperative course. Despite the reported risk for
lung failure that can be caused by CPB, none of our pa-
tients required tracheotomy or long-term ventilation
therapy with an overall ventilation time of 2.5 ± 4.9 days
(range 0 to 20), respectively 1.3 ± 0.9 days (range 1 to 4)
in hospital survivors. These findings underline the tech-
nical feasibility of CPB-usage in operations that include
Fig. 5 Actuarial overall survival after tumor resection of all patients (n = 15)
Table 2 Early and late morbidity and mortality
Patient No. Early complications/therapy Late complications/therapy Cause of death
1 in-hospital death MOF
2 superficial WHD R-CHOEP chemo, Rx
3 IABP, ECMO, bleeding, in-hospital death MOF
4 lung metastasis, chemo Pulmonary failure
5 right PLE chemo
6 haematothorax ➔ VATS Rx not possible, palliative chemo declined by patient cardio-pulmonary failure
7 PD, PLE Rx unclear
8 CNS metastasis, hypothyreoidism under chemo,
radiotherapy
9 early recurrent tumor in LA, palliative re-operation
with tumor mass reduction
cardiac failure
10 adjuvant chemo – stop due toxicity, diagnostic partial
pulmonary resections, CNS metastasis with bleeding,
palliative radiotherapy
CNS death
11 in-hospital death intraoperative right heart failure
12 intraoperative endograft implantation
for Aortic descendens rupture
N. recurrens paresis
13 chemo, Rx
14 lung metastasis 2 month after discharge tumor
15
MOF multi organ failure, WHD wound healing disorder, IABP intra-aortic balloon pump, ECMO extracorporeal membrane oxygenation, PLE pleura effusion, VATS
video-assisted thoracic surgery, PD postoperative delirium, CNS central nervous system
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increased risk of pulmonary complications during the
postoperative course.
Regarding the low incidence of tumors with only
invading the heart and/or great vessels, the cohort we
present here is quite heterogenic. In addition, extended
cardiothoracic surgery with extracorporeal bypass support
represents a high-risk therapeutic approach. Therefore,
careful patient selection and intense interdisciplinary dis-
cussion within a tumor-board is necessary to point out
candidates for surgery. Due to the tumor site and close
proximity to vital structures, even surgical salvage proce-
dures can be indicated to prevent secondary complications
e.g. tumor-embolism or cardiac tamponade. Such a “pal-
liative” strategy was aimed in 3 of our cases (patients #3,
#7 and #11). Nevertheless, all patients were free of extra-
thoracic malignant foci at time of primary decision.
Preoperative diagnosis of the very malignancy was
made in about half of our patients, of whom 5 under-
went biopsy. Hence, more interventional or open biopsy
prior to operation would have supported multi-modal
therapeutic strategies in respect of achieving complete
tumor resection e.g. by neoadjuvant therapy, which
could lead to tumor mass reduction. Four of our patients
underwent systemic induction therapy before tumor re-
section. In all other patients surgery appeared advisable
without induction therapy, either because of rapid clin-
ical deterioration at the time of diagnosis or lack of
knowledge of tumor dignity. An example for the former
situation is patient #2 (male, 35 years) who initially pre-
sented with severe progressive dyspnea at time of first
diagnosis. Imaging showed a massive mediastinal mass
with compression of the atrial cavities and superior vena
cava. In an interdisciplinary debate with respect to the
patients’ decision, early surgical resection was indicated
rather than primary chemotherapy, even though the lat-
ter would have been advised by current guidelines [21].
After macroscopically complete resection (R1, histological
diagnosis: Non Hodgkin lymphoma) and immediate relief
of his symptoms, chemo- and radiotherapy were adminis-
tered postoperatively with a favourable outcome. In
individual cases, simultaneous functional cardiac disease
requiring surgery may influence therapeutic strategy: pa-
tient #1 with diagnosis of a thymoma would formally have
required induction chemotherapy. However, that patient
had to be operated urgently due to concomitant CAD
with need of CABG. Therefore, the tumor board advised
surgical treatment in favour of induction therapy.
We describe a cohort of patients with locally advanced
disease and involvement of multiple organs or, with
respect to the heart, multiple cavities. Therefore, intra-
operative findings sometimes force to substantially mod-
ify the preoperative planned therapeutic strategy: patient
#2 was initially planned for resection without CPB.However, due to intraoperative poor hemodynamics, ini-
tiation of CPB was required to unload the heart. Local
findings in patient #3 necessitated ex vivo resection of the
tumor mass from the heart and reconstruction of the left
atrium as described by few other authors before [22, 23].
A general principle in oncological surgery is an en
bloc, complete tumor removal. The same applies for pa-
tients with locally advanced malignancies, even though
local technical and functional resectability may force the
surgeon to tolerate minimal resection margins or even
microscopic tumor residual R1). R0-status could be
achieved in 7 of our patients, R1 was found postopera-
tively in 6 patients. Albeit a very heterogenic group of
patients undergoes cardiothoracic surgery for tumor re-
moval with bypass support, acceptable survival-rates can
be observed. Park et al. reported a series of 10 patients
with an overall median survival of 21.7 months (range 3.2
to 69 months) and 33.3 months (range 3.7 to 69 months)
after surgery with incomplete resection in 7 cases. There
was no perioperative death observed [12]. In another
series of Vaporciyan et al. 19 patients were examined and
showed overall 1- and 2-year survival rates of 65 and
45 %, respectively. The authors found incomplete resec-
tion in only 4 of their patients but initially included a rela-
tively large collective (n = 8) of patients with simultaneous
extrathoracic tumor. Survival in that “palliative” group
was poorer but still reached 10.3 + − 8.6 months [8]. Com-
parable overall survival were reported by Wiebe et al. with
focus on extended pulmonary resection requiring cardio-
pulmonary bypass support. Cumulative survival in their
series was 62 % at 1 year and 53 % at 3 and 5 years, re-
spectively. Patients with histology of sarcoma showed a
better outcome than those with non-small cell carcinoma
(62.5 % vs 33 % after 1 year) [7]. Analysis of our data
showed an actuarial overall survival of 65 ± 13 % at 1 year
and 28 ± 13 % at 5 years, which is comparable to other
centers. Even though our series as well as literature re-
ports comprise only few patients with rather heterogenic
diseases survival differences depending on histology have
been observed. In contrast to Wiebe et al., we found sig-
nificant poorer survival in patients with sarcoma com-
pared to non-sarcoma. However, Wiebes series contained
many patients with non-small lung cancer whereas we
also considered other mediastinal malignancies like thym-
oma, thymic carcinoma or carcinoid tumors with substan-
tially better prognosis [7]. Sole analysis of patients with
cardiac sarcoma was recently published by Li et al. In their
series of 29 patients, they reported an overall median sur-
vival of 17 months, expectably with a significantly better
survival for R0 resection status [24]. With regard to our
single center results and overview of the current literature,
resection of malignancies invasion into the heart or great
vessels are extremely rare procedures. Main pathological
entities are sarcomas, ensued by secondary tumors with
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Surgical resection with bypass support seems feasible with
acceptable outcome even in patients with so called “pallia-
tive” intent. Complications occur occasionally during
CPB-usage and where mainly bleeding events that were
manageable by secondary revision. Even patients with in-
complete tumor removal might profit in selected cases as
well as those patients that are critically limited by mech-
anical tumor-associated symptoms. However, it is evident
that consecutive interdisciplinary discussion to determine
oncological therapy is strictly mandatory in all patients.
Conclusions
In conclusion, our review of patients with need of car-
diopulmonary bypass support for resection of central tu-
mors shows that the procedure can be performed with
tolerable risk and acceptable outcome in carefully se-
lected patients. Certainly, survival is limited but would
be presumably worse administering non-surgical therap-
ies. Therefore, well-chosen patients might benefit from
surgery even in a palliative intent. Nevertheless, meticu-
lous weighing of conservative and surgical treatment op-
tions within a tumor board is mandatory. Thus, definite
preoperative diagnosis is of paramount importance and
interventional or open biopsy should be performed if
imaging not suffices. Patients should be informed that
curative resection might be uncertain, in particular in
patients suffering from sarcoma.
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